WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Axela
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
BioSpace | March 04, 2020
Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....
Labiotech.eu | January 27, 2020
Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...
MedTech, Medical
Magenta Therapeutics | February 03, 2023
On February 2, 2023, Magenta Therapeutics, a clinical-stage biotech firm focused on enhancing stem cell transplantation, announced that it has completed a business evaluation, including a review of its programs, resources, and capabilities. Magenta has decided to cease further program development and conduct a complete examination of strategic alternatives aimed at maximizing shareholder value. Magenta will investigate potential strategic options, including, but not limited to, ...
cnbc | April 17, 2020
Biotech stocks surged Friday after new details on a closely watched clinical trial lifted hopes that scientists may be close to a treatment for the coronavirus, which continues to maintain its foothold across the globe after emerging a little over three months ago.The IBB, an ETF that tracks biotech’s biggest players, was up more than 2% Friday after health-care publication STAT News revealed early impressions from one of Gilead Sciences’ clinical trials for antiviral drug remdesivir...
Cell and Gene Therapy
Video
Medical
MedTech
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE